HR+/HER2-乳腺癌的治疗演变:从向治疗到内分泌治疗
Lu-Qi Cao1,2, Haidong Sun3, Yuhao Xie2
1Institute for Biotechnology, St. John's University, Queens, NY, United States.
本综述涵盖HR+/HER2-乳腺癌,一个主要的亚型. 它详细介绍了流行病学,分类和当前的治疗方法,如向和内分泌疗法,包括临床试验更新.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 乳腺癌是一个重大的全球健康威胁,有不同的亚型.
- HR+/HER2-乳腺癌是一种普遍的亚型,需要专注的研究和治疗策略.
研究的目的:
- 审查HR+/HER2-乳腺癌的流行病学和分类.
- 讨论HR+/HER2-乳腺癌的当前和新兴治疗方式.
主要方法:
- 对当前流行病学数据的文献综述.
- 对治疗策略的分析,包括向治疗,内分泌治疗和免疫治疗.
- 包括已完成和正在进行的临床试验数据.
主要成果:
- HR+/HER2-乳腺癌患病率和分类的总结.
- 详细讨论针对性和内分泌疗法的作用机制.
- 药物协同作用和临床试验结果的概述.
结论:
- HR+/HER2-乳腺癌的管理涉及到一个多方面的方法.
- 目前正在进行的研究和临床试验对于提高治疗疗效和患者治疗结果至关重要.
更多相关视频
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment Resistant Cancers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
